Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
Innovent and HUTCHMED Jointly Announce NMPA Conditional Approval for TYVYT® (Sintilimab Injection) in Combination with ELUNATE® (Fruquintinib) for the Treatment of Advanced Endometrial Cancer 2024-12-04 08:00
HUTCHMED Announces NMPA Approval of Surufatinib (Sulanda(R) in China) for Advanced Pancreatic Neuroendocrine Tumors 2021-06-21 15:15
Innovent and HUTCHMED Release Phase 1b preliminary Results of TYVYT (Sintilimab Injection) plus Fruquintinib as a Third Line Treatment for Advanced Colorectal Cancer at ASCO Annual Meeting 2021 2021-06-07 08:00
International companies to host live webcasts at Deutsche Bank's June 9th and 10th Depositary Receipts Virtual Investor Conference 2016-06-06 21:00
Hutchison China MediTech to present at the dbVIC - Deutsche Bank ADR Virtual Investor Conference on June 10, 2016 2016-06-06 20:30
1